背景:外用皮质类固醇恐惧症与治疗依从性差相关,在皮肤病患者中很常见。慢性手部湿疹(CHE)患者对皮质类固醇恐惧症和治疗依从性的了解有限。
目的:调查患者报告的局部皮质类固醇(TCS)结局,以及它们对CHE患者治疗依从性的影响。
方法:来自丹麦皮肤队列的CHE患者回答了包括局部皮质类固醇恐惧症(TOPICOP)量表和药物依从性报告量表(MARS-5)在内的问卷。有效率为69.2%。
结果:在CHE的927中,75.5%的人完全或几乎同意TCS损伤皮肤,48.9%的人完全或几乎同意TCS会影响他们未来的健康,36.3%的人表示对TCS有一定程度的恐惧,即使他们没有意识到任何与TCS相关的风险。大多数患者(77.9%)总是或经常尽快停止治疗,而54.8%总是或经常在开始治疗之前等待尽可能长的时间。总的来说,38.8%的人报告说他们服用的药物少于处方,54.0%的人在整个期间停止治疗。治疗依从性随着皮质类固醇恐惧症的增加而降低(p=0.004)。
结论:TOPICOP尚未在CHE患者中得到验证。
结论:皮质类固醇恐惧症在CHE患者中很常见,并且与治疗依从性呈负相关。
BACKGROUND: Topical corticosteroid phobia is associated with poor treatment adherence and is common among patients with skin disease. Knowledge about corticosteroid phobia and treatment adherence among patients with chronic hand eczema (CHE) is limited.
OBJECTIVE: Investigate patient-reported outcomes regarding topical corticosteroids (TCS), and their impact on treatment adherence in CHE patients.
METHODS: CHE patients from the Danish Skin Cohort answered a questionnaire including the Topical Corticosteroid Phobia (TOPICOP) scale and Medication Adherence Report Scale (MARS-5). Response rate was 69.2%.
RESULTS: Of 927 with CHE, 75.5% totally or almost agreed that TCS damage the skin, 48.9% totally or almost agreed that TCS would affect their future health and 36.3% reported some degree of fear of TCS even though they were unaware of any TCS-associated risks. Most patients (77.9%) always or often stop treatment as soon as possible while 54.8% always or often wait as long as possible before starting treatment. Overall, 38.8% reported that they had taken less medicine than prescribed and 54.0% had stopped treatment throughout a period. Treatment adherence decreased with increasing corticosteroid phobia (p=0.004).
CONCLUSIONS: TOPICOP has not been validated in CHE patients.
CONCLUSIONS: Corticosteroid phobia is common among CHE patients and negatively associated with treatment adherence.